Biochemical control of prostate cancer with iodine-125 brachytherapy alone: experience from a single institution

Imagem de Miniatura
Arquivos
art_NESRALLAH_Biochemical_control_of_prostate_cancer_with_iodine_125_2012.PDF (263.8 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
AMADEI, Larissa Pereira da Ponte
SILVA, Joao Luis Fernandes
HANNA, Samir Abdallah
HADDAD, Cecilia Maria Kalil
Citação
CLINICAL & TRANSLATIONAL ONCOLOGY, v.14, n.5, p.369-375, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Brachytherapy is an adequate option as monotherapy for localised prostate cancer. The objective of this study was to evaluate and compare biochemical failure free survival (BFFS) after low-dose-rate brachytherapy (LDRB) alone for patients with prostate cancer using ASTRO and Phoenix criteria, and detect prognostic factors. Data on 220 patients treated between 1998 and 2002 with LDRB were retrospectively analysed. Neoadjuvant hormone therapy was used in 74 (33.6%) patients. Median follow-up was 53.5 months (24-116). Five year BFFS was 83.0% and 83.7% using, respectively, the ASTRO and Phoenix criteria. Low -and intermediate-risk patients presented, respectively, 86.7% and 77.8% 5-year BFFS using the ASTRO definition (p=0.069), and 88.5% and 78.6% considering the Phoenix criteria (p=0.016). Bounce was observed in 66 (30%) patients. Multivariate analysis detected PSA at diagnosis < 10 ng/ml and less than 50% positive biopsy fragments as favourable prognostic factors, regarding BF using both criteria. For the Phoenix criteria, also Gleason score < 7 and low-risk group were identified as independent favourable prognostic factors. LDRB alone should be considered mostly for low-risk patients. PSA level was a strong independent prognostic factor. We support the use of the Phoenix criteria for detection of BF in patients submitted to LDRB alone.
Palavras-chave
Prostate neoplasm, Biochemical failure, Low dose-rate brachytherapy, Radiotherapy, Monotherapy
URI
https://observatorio.fm.usp.br/handle/OPI/1422
Referências
  1. Brasil. Ministerio da Saude, 2010, INC CANC BRAS
  2. Cavanagh W, 2000, Semin Urol Oncol, V18, P160
  3. Ciezki JP, 2006, INT J RADIAT ONCOL, V64, P512, DOI 10.1016/j.ijrobp.2005.07.960
  4. Critz FA, 1997, UROLOGY, V49, P322, DOI 10.1016/S0090-4295(96)00666-8
  5. Crook J, 2011, INT J RADIAT ONCOL, V80, P1323, DOI 10.1016/j.ijrobp.2010.04.038
  6. Crook JM, 1998, UROLOGY, V51, P566, DOI 10.1016/S0090-4295(97)00650-X
  7. D'Amico AV, 2000, J CLIN ONCOL, V18, P1164
  8. Fitch DL, 2006, INT J RADIAT ONCOL, V66, P1430, DOI 10.1016/j.ijrobp.2006.03.024
  9. Franca CAS, 2001, INT BRAZ J UROL, V33, P752
  10. Grimm PD, 2001, INT J RADIAT ONCOL, V51, P31, DOI 10.1016/S0360-3016(01)01601-7
  11. Guedea F, 2006, RADIOTHER ONCOL, V80, P57, DOI 10.1016/j.radonc.2006.06.004
  12. Guedea F, 2011, BRACHYTHERAPY, V10, P363, DOI 10.1016/j.brachy.2010.12.003
  13. Guedea F, 2010, CLIN TRANSL ONCOL, V12, P315, DOI 10.1007/s12094-010-0511-y
  14. HOLM HH, 1983, J UROLOGY, V130, P283
  15. Horwitz EM, 2005, J UROLOGY, V173, P797, DOI 10.1097/01.ju.0000152556.53602.64
  16. Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
  17. Kato RB, 2008, CLINICS, V63, P759, DOI 10.1590/S1807-59322008000600009
  18. Kwok Y, 2002, INT J RADIAT ONCOL, V53, P588, DOI 10.1016/S0360-3016(02)02796-7
  19. PARTIN AW, 1989, J UROLOGY, V141, P341
  20. Perez CA, 2001, INT J RADIAT ONCOL, V49, P1287, DOI 10.1016/S0360-3016(00)01492-9
  21. Pickles T, 2006, INT J RADIAT ONCOL, V64, P1355, DOI 10.1016/j.ijrobp.2005.10.008
  22. Pickles T, 2003, INT J RADIAT ONCOL, V57, P11, DOI 10.1016/S0360-3016(03)00439-5
  23. Radge H, 2000, CANCER, V89, P135
  24. Ray ME, 2006, INT J RADIAT ONCOL, V64, P1140, DOI 10.1016/j.ijrobp.2005.07.006
  25. Roach M, 2006, INT J RADIAT ONCOL, V65, P965, DOI 10.1016/j.ijrobp.2006.04.029
  26. Stamey TA, 1998, J UROLOGY, V159, P2009, DOI 10.1016/S0022-5347(01)63229-4
  27. Stock RG, 2003, INT J RADIAT ONCOL, V56, P448, DOI 10.1016/S0360-3016(02)04470-X
  28. Stock RG, 1998, INT J RADIAT ONCOL, V41, P101, DOI 10.1016/S0360-3016(98)00006-6
  29. Stock RG, 2000, CANCER, V89, P1829, DOI 10.1002/1097-0142(20001015)89:8<1829::AID-CNCR25>3.0.CO;2-9
  30. Zelefsky MJ, 1999, J CLIN ONCOL, V17, P517
  31. 2011, 2011, NCCN GUID VERS 1 PRO
  32. Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InRad